Literature DB >> 25917712

Combined flubendazole-nitazoxanide treatment of cystic echinococcosis: Pharmacokinetic and efficacy assessment in mice.

Ceballos Laura1, Elissondo Celina2, Sánchez Bruni Sergio3, Denegri Guillermo2, Lanusse Carlos3, Alvarez Luis3.   

Abstract

The current chemotherapy of cystic echinococcosis (CE) is mainly based on the use of albendazole, and the results have been shown to be highly variable. Thus, new and more efficient treatment options are urgently needed. The goals of the current study were: a) to compare the ex vivo activity of flubendazole (FLBZ) and nitazoxanide (NTZ), given either separately or co-administered, against Echinococcus granulosus protoscoleces and cysts, b) to characterize the plasma disposition kinetics of FLBZ administered alone or combined with NTZ in mice; (c) to compare the in vivo activity of FLBZ and NTZ (either each alone or as a combined treatment) against secondary CE developed in mice. Ex vivo drug activity study: E. granulosus protoscoleces and cysts were incubated either with FLBZ, NTZ, or the FLBZ-NTZ combination. Protoscoleces and cyst viability was monitored by the methylene blue exclusion test and scanning electron microscopy (SEM). Pharmacokinetic study: Balb/C mice received FLBZ (5 mg/kg) orally either alone or co-administered with NTZ (100 mg/kg). Blood samples were collected up to 12 h post treatment and plasma analyzed for FLBZ/metabolites by HPLC. Clinical Efficacy study: following secondary infection, meaning i.p. injection of 1500 E. granulosus protoscoleces/animal (n=40), the both drugs were administered by intragastric inoculation on a daily basis for a period of 25 days. Balb/C mice received FLBZ (5 mg/kg, twice a day) alone, NTZ (100 mg/kg, once daily) alone or a combination of both molecules (FLBZ, 5mg/kg twice a day and NTZ, 100 mg/kg, once daily). Ten untreated animals were used as a control. All animals were killed and the weight of the cysts collected from each animal was recorded. The presence of NTZ did not markedly affect the FLBZ kinetic parameters in mice. FLBZ alone or combined with NTZ induced a reduction (P<0.05) of cyst weight in comparison to the untreated control and NTZ-treated treated mice. The data obtained here indicate that NTZ did not affect hydatid cyst development in mice. Conversely, FLBZ shows an excellent efficacy against CE.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cystic echinococcosis; Flubendazole; Nitazoxanide

Mesh:

Substances:

Year:  2015        PMID: 25917712     DOI: 10.1016/j.actatropica.2015.04.019

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  4 in total

1.  In vivo evaluation of the efficacy of combined albedazole-IFN-α treatment for cystic echinococcosis in mice.

Authors:  Shengbin Zhang; Yongsheng Zhou; Lifu Su; Xiaodong Zhang; Hao Wang; Baoqin Liu
Journal:  Parasitol Res       Date:  2016-12-07       Impact factor: 2.289

2.  Progress in the pharmacological treatment of human cystic and alveolar echinococcosis: Compounds and therapeutic targets.

Authors:  Mar Siles-Lucas; Adriano Casulli; Roberto Cirilli; David Carmena
Journal:  PLoS Negl Trop Dis       Date:  2018-04-20

3.  Effect of nitazoxanide on albendazole pharmacokinetics in cerebrospinal fluid and plasma in rats.

Authors:  María Isabel Ruiz-Olmedo; Iliana González-Hernández; Francisca Palomares-Alonso; Javier Franco-Pérez; María de Lourdes González F; Helgi Jung-Cook
Journal:  Saudi Pharm J       Date:  2016-09-30       Impact factor: 4.330

4.  In vitro effects of tropisetron and granisetron against Echinococcus granulosus (s.s.) protoscoleces by involvement of calcineurin and calmodulin.

Authors:  Mohammad Reza Shiee; Eshrat Beigom Kia; Farzaneh Zahabiun; Mahmood Naderi; Elahe Motevaseli; Shahram Nekoeian; Majid Fasihi Harandi; Ahmad Reza Dehpour
Journal:  Parasit Vectors       Date:  2021-04-12       Impact factor: 3.876

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.